L’International Society on Thrombosis and Hemostasis ha lanciato una survey rivolta ai professionisti coinvolti nel trattamento dell’emofilia per promuovere l’informazione sulla terapia genica quale futura opzione terapeutica.

La Prof.ssa Peyvandi, il Presidente e il Direttivo AICE invitano i Soci AICE a partecipare alla survey e a diffonderla.

Clicca qui per accedere alla survey

Participate in the ISTH Baseline Survey on Gene Therapy Treatment for Hemophilia

The ISTH is pleased to announce the development of an educational roadmap that will be used to inform the creation of programs and content to increase the understanding of the global hemostasis community and prepare healthcare professionals to evaluate gene therapy as a future treatment option for hemophilia.

An international steering committee of experts, chaired by Flora Peyvandi, M.D., Ph.D., and David Lillicrap, M.D., will guide the roadmap development. Initial educational opportunities will be announced at the ISTH 2019 Congress in Melbourne, Australia, in July.

With the treatment landscape in hemophilia rapidly evolving and clinicians around the world being challenged to keep current with the latest scientific developments and clinical advancements, developing state-of-the-art clinical practice guidelines and education programs is critical to ensure best patient care,” Peyvandi said.

The ISTH will partner with the France Foundation, a renowned medical education company, for this project.

The France Foundation is pleased to collaborate with the ISTH to educate clinicians around the world about the science and potential role of gene therapy for patients with hemophilia,” said Stacy Miller, France Foundation President.

To begin the development process, the ISTH asks you to complete this brief baseline survey about gene therapy as a treatment option for hemophilia. The results of this survey will help the development of educational programs and content for physicians and other healthcare professionals involved in the care of patients with hemophilia, as well as scientists with an interest in basic, translational, and clinical research in hemophilia and gene therapy. The survey will take approximately 7 minutes to complete.